Report post

Should you buy Akba (Akba) stock in 2022?

In 2022, AKBA's revenue was $292.60 million, an increase of 37.00% compared to the previous year's $213.58 million. Losses were -$92.56 million, -67.27% less than in 2021. According to 2 analysts, the average rating for AKBA stock is "Buy." The 12-month stock price forecast is $3.0, which is an increase of 138.10% from the latest price.

What is the 12-month stock price forecast for akebia?

The 12-month stock price forecast is $3.0, which is an increase of 138.10% from the latest price. Akebia announces late filing of its second quarter earnings and Form 10-Q Akebia reaffirms 2023 net product revenue guidance of $175 - $180 million Akebia believes its cash resources as of June 30, 20...

When will Akebia Therapeutics (Akba) release its financial results?

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the first quarter ended March 31, 2023 on Monday, May 8, 2023, prior to the open of financial markets.

The World's Leading Crypto Trading Platform

Get my welcome gifts